Targeting Glycosylated PD-L1

Enhance Patients’ Anti-Cancer Immune Response

Targeting Glycosylated PD-L1 to Enhance Patients’ Anti-Cancer Immune Response

Presented by GeneTex

Speaker: Chia-Wei Li, PhD, MD Anderson Cancer Center, Texas

Content

GeneTex’s webinar explored the development of more effective cancer therapies, with particular focus on enhancing patient immunity against cancers.

  • Immunity and Cancers
  • Glycosylation of Programmed Death-Ligand 1 (PD-L1)
  • Cancer Therapies
  • GeneTex’s Featured Products

>> Your direct link to the Webinar

genetex-pd-l1